Cardiol Therapeutics Inc. (NASDAQ:CRDL) traded today at a new 52-week high of $4.29. Approximately 403,000 shares have changed hands today, as compared to an average 30-day volume of 392,000 shares.
Cardiol Therapeutics Inc. (NASDAQ:CRDL) is currently priced 16.3% above its average consensus analyst price target of $3.35.
Cardiol Therapeutics is a biotech company focused on developing therapies for inflammatory heart disease. Their lead product, CardiolRx(TM), is a pharmaceutical cannabidiol formulation being investigated in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the FDA for its investigational new drug ('IND') application for a Phase II international trial that will investigate the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age.
Over the past year, Cardiol Therapeutics Inc. has traded in a range of $1.82 to $4.29 and is now at $4.00, 120% above that low.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer